Congenital long QT syndrome

Electrical Diseases of the Heart: Genetics, Mechanisms, Treatment, Prevention

Volumn , Issue , 2008, Pages 462-482

  Ackerman, Michael J ^a   Khositseth, Anant ^b   Tester, David J ^c   Schwartz, Peter J ^d  

^a Mayo Clinic   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MAYO GRADUATE SCHOOL   (United States)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890172651     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-84628-854-8_33     Document Type: Chapter

References (103)

1. Moss AJ, Schwartz PJ. 25th anniversary of the International Long-QT Syndrome Registry: An ongoing quest to uncover the secrets of long-QT syndrome. Circulation 2005;111(9):1199-1201.
2. Jervell A, Lange-Nielsen F. Congenital deafmutism, functional heart disease with prolongation of the QT interval, and sudden death. Am Heart J 1957;54(1):59-68.
3. Romano C G G, Pongiglione R. Aritmie cardiache rare dell'eta'pediatrica. II. Accessi sincopali per fibrillazione ventricolare parossistica. Clin Peditr (Bologna) 1963;45:656-683.
4. Ward OC. A new familial cardiac syndrome in children. J Irish Med Assoc 1964;54:103-106.
5. Ackerman MJ. The long QT syndrome: Ion channel diseases of the heart. Mayo Clin Proc 1998;73(3):250-269.
6. Vincent GM. The molecular genetics of the long QT syndrome: Genes causing fainting and sudden death. Annu Rev Med 1998;49:263-274.
7. Crotti L S-B M, Pedrazzini M, Ferrandi C, Insolia R, Goulene K, Salice P, Mannarino S, Schwartz PJ. Prevalence of the long QT syndrome. Circulation 2005;112(Suppl. II):660.
8. Tester DJ, Ackerman MJ. Postmortem long QT syndrome genetic testing for sudden unexplained death in the young. J Am Coll Cardiol 2007;16;49(2):240-246.
9. Goldenberg I, Moss AJ, Zareba W, et al. Clinical course and risk stratification of patients affected with the Jervell and Lange-Nielsen syndrome. J Cardiovasc Electrophysiol 2006;17:1161-1168.
10. Moss AJ. Long QT syndromes. Curr Treat Options Cardiovasc Med 2000;2(4):317-322.
11. Schwartz PJ. Clinical applicability of molecular biology: The case of the long QT syndrome. Curr Control Trials Cardiovasc Med 2000;1(2):88-91.
12. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 1991;84(3):1136- 1144.
13. Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA 2006;296(10):1249-1254.
14. Lehmann MH, Timothy KW, Frankovich D, et al. Age-gender influence on the rate-corrected QT interval and the QT-heart rate relation in families with genotypically characterized long QT syndrome. J Am Coll Cardiol 1997;29(1):93-99.
15. Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: Findings from the International LQTS Registry. Circulation 1998;97(22):2237-2244.
16. Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators. Circulation 1998;97(5):451-456.
17. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: Gene-specific triggers for life-threatening arrhythmias. Circulation 2001;103:89-95.
18. Moss AJ, Robinson JL, Gessman L, et al. Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol 1999;84(8):876-879.
19. Ackerman MJ, Tester DJ, Porter CJ. Swimming, a gene-specific arrhythmogenic trigger for inherited long QT syndrome. Mayo Clin Proc 1999;74(11):1088-1094.
20. Moss AJ, Zareba W, Benhorin J, et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995;92(10):2929-2934.
21. Zhang L, Timothy KW, Vincent GM, et al. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation 2000;102(23):2849-2855.
22. Wilde AA, Jongbloed RJ, Doevendans PA, et al. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). J Am Coll Cardiol 1999;33(2):327-332.
23. Khositseth A, Tester DJ, Will ML, Bell CM, Ackerman MJ. Identification of a common genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. Heart Rhythm 2004;1:60-64.
24. Heradien MJ, Goosen A, Crotti L, et al. Does pregnancy increase cardiac risk for LQT1 patients with the KCNQ1-A341V mutation? J Am Coll Cardiol 2006;48:1410-1415.
25. Lehmann MH, Suzuki F, Fromm BS, et al. T wave "humps" as a potential electrocardiographic marker of the long QT syndrome. J Am Coll Cardiol 1994;24(3):746-754.
26. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med 1992;327(12):846-852.
27. Dumaine R, Wang Q, Keating MT, et al. Multiple mechanisms of Na+ channel-linked long-QT syndrome. Circ Res 1996;78(5):916-924.
28. Zareba W, Moss AJ, Schwartz PJ, et al. Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med 1998;339(14):960-965.
29. Schwartz PJ. Idiopathic long QT syndrome: Progress and questions. Am Heart J 1985;109(2):399-411.
30. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. An update. Circulation 1993;88(2):782-784.
31. Schwartz PJ. The congenital long QT syndromes from genotype to phenotype: Clinical implications. J Intern Med 2006;259(1):39-47.
32. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920;7:353-370.
33. Garson A Jr, Dick M 2nd, Fournier A, et al. The long QT syndrome in children. An international study of 287 patients. Circulation 1993;87(6):1866-1872.
34. Garson A Jr, Kertesz NJ, Towbin JA. Improved electrocardiographic identification of the long QT syndrome. J Am Coll Cardiol 2001;37(Suppl. A):467A.
35. Allan WC, Timothy K, Vincent GM, Palomaki GE, Neveux LM, Haddow JE. Long QT syndrome in children: The value of rate corrected QT interval and DNA analysis as screening tests in the general population. J Med Screen 2001;8(4):173-177.
36. Viskin S, Rosovski U, Sands AJ, et al. Inaccurate electrocardiographic interpretation of long QT: The majority of physicians cannot recognize a long QT when they see one. [See comment.] Heart Rhythm 2005;2(6):569-574.
37. Moss AJ, Schwartz PJ, Crampton RS, Locati E, Carleen E. The long QT syndrome: A prospective international study. Circulation 1985;71(1):17-21.
38. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Effect of clinical phenotype on yield of long QT syndrome genetic testing. J Am Coll Cardiol 2006;47(4):764-768.
39. Vincent GM, Timothy K, Fox J, Zhang L. The inherited long QT syndrome: From ion channel to bedside. Cardiol Rev 1999;7(1):44-55.
40. Lupoglazoff JM, Denjoy I, Berthet M, et al. Notched T waves on Holter recordings enhance detection of patients with LQt2 (HERG) mutations. Circulation 2001;103(8):1095-1101.
41. Khositseth A, Hejlik J, Shen WK, Ackerman MJ. Epinephrine-induced T-wave notching in congenital long QT syndrome. Heart Rhythm 2005;2:141-146.
42. Schwartz PJ, Malliani A. Electrical alternation of the T-wave: Clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long Q-T syndrome. Am Heart J 1975;89(1):45-50.
43. Zareba W, Moss AJ, Le Cessie S, Hall WJ. T wave alternans in idiopathic long QT syndrome. J Am Coll Cardiol 1994;23(7):1541-1546.
44. Napolitano C, Priori SG, Schwartz PJ. Significance of QT dispersion in the long QT syndrome. Prog Cardiovasc Dis 2000;42(5):345-350.
45. Day CP, McComb JM, Campbell RW. QT dispersion: An indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990;63(6):342-344.
46. Priori SG, Napolitano C, Diehl L, Schwartz PJ. Dispersion of the QT interval. A marker of therapeutic efficacy in the idiopathic long QT syndrome. Circulation 1994;89(4):1681-1689.
47. Moennig G, Schulze-Bahr E, Wedekind H, et al. Clinical value of electrocardiographic parameters in genotyped individuals with familial long QT syndrome. Pacing Clin Electrophysiol 2001;24(4 Pt. 1):406-415.
48. Vincent GM, Jaiswal D, Timothy KW. Effects of exercise on heart rate, QT, QTc and QT/QS2 in the Romano-Ward inherited long QT syndrome. Am J Cardiol 1991;68(5):498-503.
49. Swan H, Toivonen L, Viitasalo M. Rate adaptation of QT intervals during and after exercise in children with congenital long QT syndrome. Eur Heart J 1998;19(3):508-513.
50. Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 1995;92(12):3381-3386.
51. Swan H, Viitasalo M, Piippo K, Laitinen P, Kontula K, Toivonen L. Sinus node function and ventricular repolarization during exercise stress test in long QT syndrome patients with KvLQT1 and HERG potassium channel defects. J Am Coll Cardiol 1999;34(3):823-829.
52. Ackerman MJ, Khositseth A, Tester, DJ, Hejlik J, Shen WK, Porter CJ. Epinephrine-induced QT interval prolongation: A gene-specific paradoxical response in congenital long QT syndrome. Mayo Clin Proc 2002;77(5):413-421.
53. Shimizu W, Noda T, Takaki H, et al. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. J Am Coll Cardiol 2003;41(4):633-642.
54. Vyas H, Hejlik J, Ackerman MJ. Epinephrine QT stress testing in the evaluation of congenital long-QT syndrome: Diagnostic accuracy of the paradoxical QT response. Circulation 2006;113(11):1385-1392.
55. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80(5):795-803.
56. Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995;80(5):805-811.
57. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm 2005;2:507-517.
58. Napolitano C, Priori SG, Schwartz PJ, et al. Genetic testing in the long QT syndrome: Development and validation of an efficient approach to genotyping in clinical practice. [See comment.] JAMA 2005;294(23):2975-2980.
59. Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000;102(10):1178-1185.
60. Westenskow P, Splawski I, Timothy KW, Keating MT, Sanguinetti MC. Compound mutations: A common cause of severe long-QT syndrome. Circulation 2004;109:1834-1841.
61. Ackerman MJ, Tester DJ, Jones G, Will MK, Burrow CR, Curran M. Ethnic differences in cardiac potassium channel variants: Implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clinic Proc 2003;78:1479-1487.
62. Ackerman MJ, Splawski I, Makielski JC, et al. Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: Implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing. Heart Rhythm 2004;1:600-607.
63. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001;22(16):1374-1450.
64. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348:1866-1874.
65. Schwartz PJ, Spazzolini C, Crotti L, et al. The Jervell and Lange-Nielsen syndrome: Natural history, molecular basis, and clinical outcome. Circulation 2006;113(6):783-790.
66. Marks ML, Trippel DL, Keating MT. Long QT syndrome associated with syndactyly identified in females. Am J Cardiol 1995;76(10):744-745.
67. Splawski I, Timothy KW, Sharpe LM, et al. Cav1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004;119:19-31.
68. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000;101(6):616-623.
69. Malfatto G, Beria G, Sala S, Bonazzi O, Schwartz PJ. Quantitative analysis of T wave abnormalities and their prognostic implications in the idiopathic long QT syndrome. J Am Coll Cardiol 1994;23(2):296-301.
70. Atiga WL, Calkins H, Lawrence JH, Tomaselli GF, Smith JM, Berger RD. Beat-to-beat repolarization lability identifies patients at risk for sudden cardiac death. J Cardiovasc Electrophysiol 1998;9(9):899-908.
71. Zareba W. New electrocardiographic indices of risk stratification. J Electrocardiol 2001;34:332.
72. Steinbigler P, Haberl R, Nespithal K, Spiegl A, Schmucking I, Steinbeck G. T wave spectral variance: A new method to determine inhomogeneous repolarization by T wave beat-to-beat variability in patients prone to ventricular arrhythmias. J Electrocardiol 1998;30(Suppl.):137-144.
73. Bhandari AK, Shapiro WA, Morady F, Shen EN, Mason J, Scheinman MM. Electrophysiologic testing in patients with the long QT syndrome. Circulation 1985;71(1):63-71.
74. Nemec J, Ackerman, MJ, Tester D, Hejlik J, Shen WK. Catecholamine provoked microvoltage T wave alternans in genotyped long QT syndrome. Pacing Clin Electrophysiol 2003;26(8):1660-1667.
75. Nemec J, Hejlik JB, Shen WK, Ackerman MJ. Catecholamine-induced T-wave lability in congenital long QT syndrome: a novel phenomenon associated with syncope and cardiac arrest. Mayo Clin Proc 2003;78:40-50.
76. Priori SG, Maugeri FS, Schwartz PJ. The risk of sudden death as first cardiac event in asymptomatic patients with the long QT syndrome. Circulation 1998;98(Suppl. I):777 (abstract).
77. Schwartz PJ. The long QT syndrome. Curr Probl Cardiol 1997;22(6):297-351.
78. Chatrath R, Bell CM, Ackerman MJ. Beta-blocker therapy failures in symptomatic probands with genotyped long-QT syndrome. Pediatr Cardiol 2004;25(5):459-465.
79. Viskin S, Fish R, Zeltser D, et al. Arrhythmias in the congenital long QT syndrome: How often is torsade de pointes pause dependent? Heart 2000;83(6):661-666.
80. Eldar M, Griffin JC, Van Hare GF, et al. Combined use of beta-adrenergic blocking agents and longterm cardiac pacing for patients with the long QT syndrome. J Am Coll Cardiol 1992;20(4):830-837.
81. Dorostkar PC, Eldar M, Belhassen B, Scheinman MM. Long-term follow-up of patients with long-QT syndrome treated with beta-blockers and continuous pacing. Circulation 1999;100(24):2431-2436.
82. Tan HL, Bardai A, Shimizu W, et al. Genotypespecific onset of arrhythmias in congenital long-QT syndrome: Possible therapy implications. Circulation 2006;114:2096-2103.
83. Chatrath R, Porter CJ, Ackerman MJ. Role of transvenous implantable cardioverter-defibrillators in preventing sudden cardiac death in children, adolescents, and young adults. Mayo Clin Proc 2002;77:226-231.
84. Zareba W, Moss AJ, Daubert JP, Hall WJ, Robinson JL, Andrews M. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol 2003;14:337-341.
85. Monnig G, Kobe J, Loher A, et al. Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: A long-term follow-up. Heart Rhythm 2005;2(5):497-504.
86. Villain E, Denjoy I, Lupoglazoff JM, et al. Low incidence of cardiac events with B-blocking therapy in children with long QT syndrome. Eur Heart J 2004;25:1405-1411.
87. Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 2000;35(3):778-786.
88. Schwartz PJ, Locati E. The idiopathic long QT syndrome: Pathogenetic mechanisms and therapy. Eur Heart J 1985;6(Suppl. D):103-114.
89. Moss AJ, McDonald J. Unilateral cervicothoracic sympathetic ganglionectomy for the treatment of long QT interval syndrome. N Engl J Med 1971;285(16):903-904.
90. Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 2004;109(15):1826-1833.
91. Compton SJ, Lux RL, Ramsey MR, et al. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation 1996;94(5):1018-1022.
92. Etheridge SP, Compton SJ, Tristani-Firouzi M, Mason JW. A new oral therapy for long QT syndrome: Long-term oral potassium improves repolarization in patients with HERG mutations. J Am Coll Cardiol 2003;42:1777-1782.
93. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with B-blockers. JAMA 2004;292:1341-1344.
94. Shimizu W, Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 1997;96(6):2038-2047.
95. Shimizu W, Antzelevitch C. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: Effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation 1998;98(21):2314-2322.
96. Moss AJ, Windle JR, Hall WJ, et al. Safety and efficacy of flecainide in subjects with long QT-3 syndrome (DeltaKPQ mutation): A randomized, doubleblind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol 2005;10(4Suppl.):59-66.
97. Khan IA, Gowda RM. Novel therapeutics for treatment of long-QT syndrome and torsade de pointes. Int J Cardiol 2004;95(1):1-6.
98. Priori SG, Napolitano C, Schwartz PJ, Bloise R, Crotti L, Ronchetti E. The elusive link between LQT3 and Brugada syndrome: The role of flecainide challenge. Circulation 2000;102:945-947.
99. Vyas H, Johnson J, Houlihan R, Bauer BA, Ackerman MJ. Acquired long QT syndrome secondary to cesium chloride supplement. J Altern Complement Med 2006;12(10):1011-1014
100. Fitzgerald PT, Ackerman MJ. Drug-induced torsades de pointes: The evolving role of pharmacogenetics. Heart Rhythm 2005;2:S30-S37.
101. Zipes DP, Ackerman MJ, Estes NA 3rd, Grant AO, Myerburg RJ, Van Hare G. Task Force 7: Arrhythmias. J Am Coll Cardiol 2005;45:1354-1363.
102. Maron BJ, Isner JM, McKenna WJ. 26th Bethesda conference: Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: Hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. J Am Coll Cardiol 1994;24(4):880-885.
103. Taggart NW, Haglund CM, Tester DJ, Ackerman MJ. Diagnostic miscues in congenital long QT syndrome. Circulation 2007;115:2613-2620.